LifeTime and improving European healthcare through cell-based interceptive medicine

Nikolaus Rajewsky*, Geneviève Almouzni*, Stanislaw A. Gorski*, Stein Aerts, Ido Amit, Michela G. Bertero, Christoph Bock, Annelien L. Bredenoord, Giacomo Cavalli, Susanna Chiocca, Hans Clevers, Bart de Strooper, Angelika Eggert, Jan Ellenberg, Xosé M. Fernández, Marek Figlerowicz, Susan M. Gasser, Norbert Hubner, J. rgen Kjems, J. rgen A. KnoblichGrietje Krabbe, Peter Lichter, Sten Linnarsson, Jean-Christophe Marine, John Marioni, Marc A. Marti-Renom, Mihai G. Netea, D. rthe Nickel, Marcelo Nollmann, Halina R. Novak, Helen Parkinson, Stefano Piccolo, Inês Pinheiro, Ana Pombo, Christian Popp, Wolf Reik, Sergio Roman-Roman, Philip Rosenstiel, Joachim L. Schultze, Oliver Stegle, Amos Tanay, Giuseppe Testa, Dimitris Thanos, Fabian J. Theis, Maria-Elena Torres-Padilla, Alfonso Valencia, C. line Vallot, Alexander van Oudenaarden, Marie Vidal, Thierry Voet, LifeTime Community

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

LifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
Original languageEnglish
JournalNature
DOIs
Publication statusE-pub ahead of print - 2020

Cite this